Catyalyst Pharmaceutical (CPRX) Posts Narrower than Expected Q1 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts CPRX Hot Sheet
Price: $31.49 --0%
Financial Fact:
Total operating costs and expenses: 3.91M
Today's EPS Names:
FUSE, INM, TRI, More
Financial Fact:
Total operating costs and expenses: 3.91M
Today's EPS Names:
FUSE, INM, TRI, More
Join SI Premium – FREE
Catyalyst Pharmaceutical Partners (NASDAQ: CPRX) reported Q1 EPS of ($0.04), $0.04 better than the analyst estimate of ($0.08).
For earnings history and earnings-related data on Catyalyst Pharmaceutical Partners (CPRX) click here.
For earnings history and earnings-related data on Catyalyst Pharmaceutical Partners (CPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ultragenyx Pharma (RARE) Misses Q3 EPS by 6c; Offers Guidance
- Everus Construction Group, Inc. (ECG) Tops Q3 EPS by 101c ; Offers Guidance
- Ovintiv Inc. (OVV) Tops Q3 EPS by 3c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
